{"filings":[{"id":99361,"accession_number":"0000879169-26-000023","cik":879169,"company_name":"INCYTE CORP","ticker":"INCY","form_type":"8-K","filed_at":"2026-04-28T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Incyte Q1 revenue $1.27B (+21% YoY), Non-GAAP EPS $1.81 beats prior $1.16; pipeline expands","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total net sales $1.10B (+20% YoY); Jakafi $758M (+7%), Opzelura $143M (+20%), Hem/Onc $204M (+116%).","GAAP net income $303M ($1.47 diluted EPS) vs $158M ($0.80) prior year; Non-GAAP diluted EPS $1.81.","Positive Phase 3 vitiligo results for povorcitinib; NDA accepted for HS; four product approvals/launches expected in next 12 months.","Appointed Suketu Upadhyay as CFO effective May 4, 2026; cash position $4.0B.","FY 2026 guidance reaffirmed: total net sales $4.77-$4.94B; R&D and SG&A expenses guided."],"consensus_eps_estimate":null,"consensus_eps_actual":1.47,"consensus_revenue_estimate":null,"consensus_revenue_actual":1272676000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":19446794201.310402,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":115310,"accession_number":"0000879169-26-000018","cik":879169,"company_name":"INCYTE CORP","ticker":"INCY","form_type":"8-K","filed_at":"2026-03-30T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Incyte director Susanne Schaffert resigns from board effective April 15","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Susanne Schaffert notified Incyte of resignation from Board on March 26, 2026.","Resignation effective April 15, 2026; not due to any disagreement with the company.","Dr. Schaffert had served on the Board since 2022."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":19446794201.310402,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":115309,"accession_number":"0000879169-26-000016","cik":879169,"company_name":"INCYTE CORP","ticker":"INCY","form_type":"8-K","filed_at":"2026-03-26T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Incyte appoints Cagnoni as President, integrates U.S. commercial; Trotta departs","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Pablo Cagnoni named President, Incyte and Global Head of R&D; replaces Bill Meury as President; Meury remains CEO.","Steven Stein promoted to EVP, Chief Medical Officer and Head of Late-stage Development.","Mohamed Issa becomes EVP and Head of U.S. Commercial; U.S. oncology and immunology teams integrated.","Matteo Trotta, EVP and GM of U.S. Dermatology, will leave Incyte after a transition period.","No changes to compensation for the impacted executives in connection with these title changes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":19446794201.310402,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":115308,"accession_number":"0000879169-26-000013","cik":879169,"company_name":"INCYTE CORP","ticker":"INCY","form_type":"8-K","filed_at":"2026-03-06T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"FDA issues Complete Response Letter for Incyte's Zynyz in NSCLC due to facility inspection findings","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA CRL for Zynyz (retifanlimab) sBLA for metastatic NSCLC with platinum chemo, citing Catalent Indiana inspection findings.","CRL did not cite efficacy or safety concerns; Zynyz's data from Phase 3 POD1UM-304 trial remains positive.","Incyte working with FDA and Catalent Indiana to address CRL and support potential sBLA resubmission.","The inspection findings at Catalent Indiana (part of Novo Nordisk) are not specific to Zynyz.","No other approvability issues raised; drug substance manufacturer not a concern."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":19446794201.310402,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":115307,"accession_number":"0000879169-26-000006","cik":879169,"company_name":"INCYTE CORP","ticker":"INCY","form_type":"8-K","filed_at":"2026-02-10T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Incyte Q4 total revenue $1.51B (+28% YoY); FY 2025 net product revenue beat guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 total revenue $1.51B (+28% YoY); net product revenue $1.22B (+20%). FY 2025 net product revenue $4.35B, above $4.23-4.32B guidance.","GAAP diluted EPS Q4 $1.46, FY $6.41; non-GAAP diluted EPS Q4 $1.80, FY $6.80.","2026 total net product revenue guidance $4.77-4.94B, including Jakafi $3.22-3.27B and Opzelura $750-790M.","Pipeline: positive frontMIND Phase 3 for tafasitamab in DLBCL; Jakafi XR filing submitted, decision mid-2026; INCA033989 registrational plans; ruxolitinib cream PN paused.","Cash $3.6B; entered option agreement with Prelude Therapeutics for JAK2V617F inhibitor program ($100M option exercise)."],"consensus_eps_estimate":null,"consensus_eps_actual":6.41,"consensus_revenue_estimate":null,"consensus_revenue_actual":5141242000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":19446794201.310402,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":131729,"accession_number":"0000879169-25-000122","cik":879169,"company_name":"INCYTE CORP","ticker":"INCY","form_type":"8-K","filed_at":"2025-12-12T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Incyte director Hervé Hoppenot retires from board effective Dec 10, 2025","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Hervé Hoppenot retired from Incyte's Board of Directors effective December 10, 2025.","Hoppenot is the former Chairman and CEO of Incyte, serving as a director since 2014.","No replacement or additional board changes were announced in the filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":19446794201.310402,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":131728,"accession_number":"0000879169-25-000115","cik":879169,"company_name":"INCYTE CORP","ticker":"INCY","form_type":"8-K","filed_at":"2025-10-28T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Incyte Q3 revenue $1.37B (+20% YoY); raises FY 2025 product revenue guidance to $4.23-4.32B","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["GAAP diluted EPS $2.11 vs $0.54 YoY; Non-GAAP diluted EPS $2.26 vs $1.07.","Jakafi net revenue $791M (+7%), Opzelura $188M (+35%), Niktimvo $46M (launch).","Raised FY 2025 Jakafi guidance to $3.05-3.075B, other oncology to $550-575M.","FDA approved Opzelura for pediatric atopic dermatitis (age 2+).","Plan to start registrational program for INCA33890 in MSS CRC in 2026; paused INCA034460, INCB57643, povorcitinib in CSU."],"consensus_eps_estimate":null,"consensus_eps_actual":4.95,"consensus_revenue_estimate":null,"consensus_revenue_actual":3634407000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":19446794201.310402,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":131727,"accession_number":"0001104659-25-096632","cik":879169,"company_name":"INCYTE CORP","ticker":"INCY","form_type":"8-K","filed_at":"2025-10-03T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Incyte appoints Thomas Tray as principal financial officer effective Sept 16, 2025","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Thomas Tray, age 48, was appointed as principal financial officer, effective September 16, 2025.","Mr. Tray currently serves as VP, Finance and Chief Accounting Officer (principal accounting officer).","He joined Incyte in June 2005 as Manager, External Reporting and has held roles of increasing responsibility.","No arrangements or understandings existed for his appointment; no family relationships with directors or executive officers.","Mr. Tray holds a B.S. in Accounting from Mount Saint Mary's University and an Executive MBA from Saint Joseph's University."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":19446794201.310402,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":148303,"accession_number":"0000879169-25-000108","cik":879169,"company_name":"INCYTE CORP","ticker":"INCY","form_type":"8-K","filed_at":"2025-08-07T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Incyte CFO Christiana Stamoulis to step down effective September 16, 2025","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["CFO Christiana Stamoulis notified Incyte of her resignation to pursue another opportunity.","Departure effective September 16, 2025; she will remain to support transition.","Company has initiated process to appoint a successor CFO."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":19446794201.310402,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":148302,"accession_number":"0000879169-25-000100","cik":879169,"company_name":"INCYTE CORP","ticker":"INCY","form_type":"8-K","filed_at":"2025-07-29T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Incyte Q2 2025 revenue up 16% to $1.216B; raised Jakafi and oncology guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenues $1.216B (+16% YoY); net product rev $1.059B (+17% YoY). GAAP EPS $2.04 diluted, vs $(2.04) loss a year ago.","Jakafi net rev $764M (+8%); full-year guidance raised to $3.0-3.05B (prev $2.95-3.0B). Opzelura $164M (+35%).","Niktimvo launch strong with Q2 rev $36M; other oncology guidance raised to $500-520M (prev $415-455M).","New CEO Bill Meury appointed June 26, 2025 upon retirement of Hervé Hoppenot.","Novartis royalty dispute settled; Jakafi royalty rate reduced by 50% starting Jan 1, 2025; $280M paid in settlement."],"consensus_eps_estimate":null,"consensus_eps_actual":2.84,"consensus_revenue_estimate":null,"consensus_revenue_actual":2268427000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":19446794201.310402,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":167085,"accession_number":"0001104659-25-063675","cik":879169,"company_name":"INCYTE CORP","ticker":"INCY","form_type":"8-K","filed_at":"2025-06-27T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Incyte appoints William J. Meury as President and CEO; Hervé Hoppenot retires","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Hervé Hoppenot retired as President & CEO effective June 26, 2025; will serve as special advisor for up to one year.","William J. Meury appointed President & CEO effective June 26, 2025; also joins the Board.","Meury receives base salary of $1.25M, target bonus 100%, and equity awards including sign-on PSUs with stock price hurdles.","Julian C. Baker, Lead Independent Director, assumes role of Chairman of the Board.","Board amends 2024 Inducement Stock Incentive Plan to increase authorized shares from 1M to 2M."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":19446794201.310402,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":167084,"accession_number":"0000879169-25-000062","cik":879169,"company_name":"INCYTE CORP","ticker":"INCY","form_type":"8-K","filed_at":"2025-06-11T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Incyte shareholders approve 8.5M share increase in stock incentive plan, 1M in ESPP","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Stock incentive plan amendment approved: shares increased from 66.5M to 75.0M, plan extended 5 years.","ESPP amendment approved: shares reserved increased from 10.35M to 11.35M.","All 9 director nominees elected; advisory say-on-pay passed with 91% of votes cast.","Ernst & Young ratified as independent auditor for FY2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":19446794201.310402,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":167083,"accession_number":"0000879169-25-000059","cik":879169,"company_name":"INCYTE CORP","ticker":"INCY","form_type":"8-K","filed_at":"2025-05-14T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Incyte settles JAKAFI royalty dispute with Novartis; pays $280M vs $537M accrued","summary_kind":"llm","event_type":"litigation","confidence":"high","bullets":["Settlement resolves litigation over royalty duration under 2009 Collaboration and License Agreement.","Incyte to pay Novartis $280M; had $537.1M accrued as of March 31, 2025.","Royalty rate on future U.S. JAKAFI net sales reduced by 50% effective Jan 1, 2025.","Reduced royalty for Q1 2025 is ~$14.9M; $242.2M difference to be recorded in Q2 2025.","Settlement eliminates contingent liability and lowers future royalty expense."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":19446794201.310402,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":167082,"accession_number":"0000879169-25-000053","cik":879169,"company_name":"INCYTE CORP","ticker":"INCY","form_type":"8-K","filed_at":"2025-04-29T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Incyte Q1 2025 revenues up 20% to $1.05B; Jakafi guidance raised","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenues $1,053M (+20% YoY); product rev $922M (+26%); GAAP diluted EPS $0.80; Non-GAAP $1.16.","Jakafi net product rev $709M (+24%); full-year 2025 guidance raised to $2,950-$3,000M.","Opzelura net rev $119M (+38%); Niktimvo launch rev $14M in first two months.","Povorcitinib meets primary endpoints in Phase 3 HS and Phase 2 CSU; supports regulatory submission.","Cash and marketable securities $2.4B; pipeline progress across MPN, oncology, and IAI programs."],"consensus_eps_estimate":null,"consensus_eps_actual":0.8,"consensus_revenue_estimate":null,"consensus_revenue_actual":1052898000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":19446794201.310402,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":184450,"accession_number":"0001628280-25-004514","cik":879169,"company_name":"INCYTE CORP","ticker":"INCY","form_type":"8-K","filed_at":"2025-02-10T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Incyte Q4 2024 revenue $1.18B (+16% YoY), guides 2025 Jakafi $2.93-2.98B, Opzelura $630-670M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 total revenues $1.18B (+16% YoY); full year $4.24B (+15%). GAAP diluted EPS $1.02 (Q4), $0.15 (FY); Non-GAAP $1.43 (Q4), $1.08 (FY).","Jakafi net revs Q4 $773M (+11% YoY), FY $2.79B (+8%); Opzelura Q4 $162M (+48%), FY $508M (+50%).","FY2025 guidance: Jakafi $2,925-2,975M; Opzelura $630-670M; other oncology $415-455M.","Pipeline catalysts: Niktimvo launched; ruxolitinib XR bioequivalence met, submission by year-end 2025; four pivotal readouts in 2025.","Cash and securities $2.2B at Dec 31, 2024, down from $3.7B due to $2B share repurchase and $783M Escient acquisition."],"consensus_eps_estimate":null,"consensus_eps_actual":0.15,"consensus_revenue_estimate":null,"consensus_revenue_actual":4241217000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":19446794201.310402,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":184449,"accession_number":"0000879169-25-000011","cik":879169,"company_name":"INCYTE CORP","ticker":"INCY","form_type":"8-K","filed_at":"2025-01-10T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Incyte EVP North America Barry Flannelly retires; successor starts Jan 6","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Barry P. Flannelly, EVP General Manager North America, retired effective Jan 6, 2025.","He will remain employed through July 31, 2025 to assist with transition.","Successor commenced employment on Jan 6; name not disclosed in filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":19446794201.310402,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":201043,"accession_number":"0000879169-24-000169","cik":879169,"company_name":"INCYTE CORP","ticker":"INCY","form_type":"8-K","filed_at":"2024-10-29T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Incyte Q3 2024 revenues up 24% to $1.14B; Jakafi guidance raised","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenues $1.138B (+24% YoY); Jakafi net revenue $741M (+16%); Opzelura $139M (+52%).","GAAP diluted EPS $0.54 vs $0.76 YoY; Non-GAAP diluted EPS $1.07 vs $1.10.","Jakafi 2024 guidance raised to $2.74-2.77B; Other Heme/Onco guidance reduced to $310-320M.","FDA approved Niktimvo (axatilimab) for chronic GVHD; sNDA filed for ruxolitinib cream in pediatric AD.","Phase 3 retifanlimab in SCAC and tafasitamab in FL met endpoints; sBLAs planned by end of 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.8,"consensus_revenue_estimate":null,"consensus_revenue_actual":3062519000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":19446794201.310402,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":217054,"accession_number":"0000879169-24-000146","cik":879169,"company_name":"INCYTE CORP","ticker":"INCY","form_type":"8-K","filed_at":"2024-07-30T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Q2 net loss $445M; revs up 9% to $1.04B; Jakafi guidance raised; $2B buyback completed","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenues $1,044M (+9% YoY); Jakafi $706M (+3%), Opzelura $122M (+52%).","GAAP net loss $444.6M vs $203.5M income in Q2 2023; non-GAAP net loss $396.1M.","Completed $2.0B share repurchase (33.3M shares at $60 each) in June 2024.","Raised low end of 2024 Jakafi revenue guidance to $2,710-$2,750M; revised R&D guidance up.","Discontinued development of oral PD-L1, LAG-3, TIM-3, LAG-3xPD-1; focus on high-impact programs."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.24,"consensus_revenue_estimate":null,"consensus_revenue_actual":1924648000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":19446794201.310402,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":217053,"accession_number":"0001104659-24-077770","cik":879169,"company_name":"INCYTE CORP","ticker":"INCY","form_type":"8-K","filed_at":"2024-07-03T23:59:59+00:00","items":["1.01","2.03"],"status":"ready","headline":"Incyte extends revolving credit facility maturity to June 2027","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Maturity of revolving credit facility extended from Aug 18, 2024 to June 28, 2027.","Amendment No. 2 entered on June 28, 2024; full agreement to be filed with Q2 2024 10-Q.","Incyte Holdings Corporation remains a guarantor; J.P. Morgan Chase is administrative agent.","No change to total commitment amount or other material terms disclosed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":19446794201.310402,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":236823,"accession_number":"0000879169-24-000082","cik":879169,"company_name":"INCYTE CORP","ticker":"INCY","form_type":"8-K","filed_at":"2024-06-14T23:59:59+00:00","items":["5.07","9.01"],"status":"ready","headline":"Incyte shareholders elect all 9 directors, approve executive compensation, ratify auditor at 2024 annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["All nine director nominees elected with at least 171M votes for (89.6% to 99.4% of votes cast).","Non-binding advisory vote on named executive officer compensation approved: 171.7M for (89.6%).","Ratification of Ernst & Young as independent auditor approved: 186.6M for (92.3%)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.15,"market_cap_usd":19446794201.310402,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":236822,"accession_number":"0001104659-24-060207","cik":879169,"company_name":"INCYTE CORP","ticker":"INCY","form_type":"8-K","filed_at":"2024-05-13T23:59:59+00:00","items":["1.01","7.01","9.01"],"status":"ready","headline":"Incyte commences $1.672B Dutch auction tender offer, agrees to buy $328M from Baker Entities","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Incyte commences modified Dutch auction tender offer to repurchase up to $1.672 billion of common stock at $52-$60 per share.","Incyte enters stock purchase agreement with Baker Entities (own ~16.4% of shares) to buy up to $328 million at same price to maintain their ownership.","Total repurchase up to $2.0 billion, representing ~14.8%-17.1% of outstanding shares as of May 9, 2024.","Tender offer expires June 10, 2024; Baker Entities purchase expected 11 business days after offer completion.","Baker Entities include Julian C. Baker (board member) and entities advised by Baker Bros. Advisors LP."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":19446794201.310402,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":236821,"accession_number":"0000879169-24-000074","cik":879169,"company_name":"INCYTE CORP","ticker":"INCY","form_type":"8-K","filed_at":"2024-04-30T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Incyte Q1 revenues $881M (+9% YoY), GAAP EPS $0.75; to acquire Escient for $750M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $881M (+9% YoY); GAAP net income $169.5M, diluted EPS $0.75.","Jakafi net revenues $572M (-1% YoY) despite 5% paid patient growth; inventory drawdown of ~$55M.","Opzelura revenues $86M (+52% YoY) driven by AD and vitiligo uptake.","Incyte to acquire Escient Pharmaceuticals for $750M plus net cash; lead candidate EP262 for CSU.","FY2024 guidance reaffirmed: Jakafi $2.69-2.75B; R&D $1.72-1.76B."],"consensus_eps_estimate":null,"consensus_eps_actual":0.75,"consensus_revenue_estimate":null,"consensus_revenue_actual":880889000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":19446794201.310402,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}